← Leaderboards
Ronald Lennox
Adiutrix Therapeutics
$688,792
Attributed
$1,377,583
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2024–25$2M$1.5M$1M$500K$0
'24
'25
Funding mix
By agency
NIH$1,377,583 · 1
By mechanism
R42$1,377,583 · 1
Top collaborators
- Randi Beth Silver2 shared
Others in their field
Other Rising Stars on “Active Sites”
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
- Mari Ostendorf · University Of Washington$51,931,230
- Sabrina Paganoni · Massachusetts General Hospital$32,226,701
- Suma Babu · Massachusetts General Hospital$32,226,701
- Bambra Stokes · Ppd Development Lp$17,155,112
- Alanna Maguire · Mayo Clinic Rochester$16,353,346
Research focus
Active SitesAffectAnalogAnimal ModelAntifibrotic TreatmentBindingBinding SitesBleomycinBody SystemCessation Of LifeChronic Kidney FailureCollagenComplexCostCrohn&AposDesignDisease ProgressionDrug EfficacyDrug TargetingEffective TherapyEnzymesEnzyme SubstrateEuropeActins
Grant awards (2)
Platform technology to identify and develop first-in-class anti-fibrotic therapeutics through inhibition of collagen CP4H$1,027,583
R42 · FY2025 · HL · contact PI
Platform technology to identify and develop first-in-class anti-fibrotic therapeutics through inhibition of collagen CP4H$350,000
R42 · FY2024 · HL · contact PI